Abstract

Introduction: Cisplatin-based chemotherapy improved survival and quality of life in lung cancer. The aim of this study is to evaluate the feasibility of the cisplatin-vinorelbine (day 1+8) in patients with metastatic NSCLC.

Material and Method: ECOG performance 0-1, chemotherapy- naive stage IV NSCLC patients were treated with cisplatin (75 mg/m2, d1) and vinorelbine (30 mg/m2, d1 and d8, IV) every 21 days for a maximum of 6 cycles in a single center. Between October 2001 and December 2006, a total of 44 NSCLC patients were evaluated.

Results: Characteristics of patients were as follows: Median age 56 years (range 41-72), male 41, female 3 and PS 0=7 / PS 1=37. The histologic diagnosis was adenocarcinoma in 17 patients, squamous cell carcinoma in 5 and undifferentiated NSCLC in 22. Brain metastases were present in 7 patients (16%) prior to starting the treatment. Median number of cycles was 3.0 (range 1-6). Complete responses were seen in 1 patient (2.3%), partial response in 15 (34.1%) and disease stabilization in 19 (43.2%). In a total of 140 cycles, grade 3-4 neutropenia, leucopenia and anemia occurred in 16.5%, 10% and 0.7% respectively. One fatal event was observed. The median survival was 285 days (95% CI [172-397]) and at 1 and 2 years survival were 39% and 9.5%, respectively.

Conclusion: The combination of cisplatin plus vinorelbine is an active regimen with infrequent toxicity in patients with metastatic NSCLC. (Tur Toraks Der 2008;9:137-40)